Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries

Trial Profile

Multicenter Randomized Study of the MiStent Sirolimus Eluting Absorbable Polymer Stent System (MiStent SES) for Revascularization of Coronary Arteries

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 May 2018

At a glance

  • Drugs Sirolimus (Primary) ; Everolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms DESSOLVE III
  • Most Recent Events

    • 23 May 2018 24-month results and update from optical coherence tomography (OCT) sub-study presented this week at EuroPCR 2018, as reported in a Micell Technologies media release.
    • 23 May 2018 24-month results published in the Micell Technologies Media Release
    • 06 Dec 2017 Results published in the Micell Technologies Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top